FDA Audits and Protocol Complexity
An increasing amount of public data on clinical trial research has become available, including ClinicalTrials.gov and Open Payments.
An increasing amount of public data on clinical trial research has become available, including ClinicalTrials.gov and Open Payments. In addition, Europe has developed equivalent databases, or is in the process of developing them. The FDA has made its global site audit results available for some time to the public. The number of audits increased substantially, growing from 1,185 in 2008 to 10,264 in 2013, the last full year available. The summary results do indicate that up to 2010, the FDA increased the number of audits outside the United States. However, since 2011, the percentage of sites audited outside the United States has remained stable at 26% to 28%.
Publicly available data allow us to quantify variables across organization and therapeutic areas that may be associated with such considerations as study completion times and results. Importantly, conclusions based upon these public data lend themselves to third-party interrogation. A recent Wall Street Journal article for instance indicated that the FDA compliance issues reported for 46% of all audits indicated increasing protocol complexity. However, a review of the public FDA data does not support this assertion.
The FDA reports the results of their audits in three major categories, with more detail also available: no action indicated (NAI), official action indicated (OAI) and voluntary action indicated (VAI). Since 2008 there has been virtually no change in the audit results. An older study by the author1 demonstrated that site experience, rather than protocol design, was the major variable associated with the severity of audit results. Smaller and less experienced sites were far more likely to be cited for compliance issues. Protocols may indeed be becoming more complex, but the FDA audit results do not allow us to draw that conclusion.
Source: FDA.gov, BIMO Inspection Classification Database, March 2015.
1H. Glass, “FDA Audit Results as an Investigator Evaluation Tool,” Applied Clinical Trials,, Volume 6, Number 4, April 1997
*The author wishes to thank Ankit Lodaya, a PhD student at the University, for gathering the FDA audit data.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
